Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine
Clinical trial NCT05576623 · COMPLETED
Trial details
- NCT number
- NCT05576623
- Sponsor
- Cellid Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-14
- Primary completion
- 2023-03-10
- Enrollment
- 320
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.